Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX ORLADEYO — Total revenues

Similar metrics at other companies

Supernus Pharmaceuticals logo
SUPNONAPGO — Total revenues
$8.38M—
Ligand Pharmaceuticals logo
LGNDOhtuvayre — Total revenues and income
$2.99M+112%
Crescent Energy logo
CRGYOil — Total revenues
$893.32M+44.2%
Supernus Pharmaceuticals logo
SUPNOxtellar XR — Total revenues
$7.42M-27.2%
PBH
PBHOral Care — Total revenues
$28M+3.3%
PBH
PBHOther revenues — Total revenues
$2.96M+818%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's orladeyo — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's ORLADEYO — total revenues?
BioCryst Pharmaceuticals (BCRX) reported ORLADEYO — total revenues of $148.35M in Q1 2026.
How has BioCryst Pharmaceuticals's ORLADEYO — total revenues changed year-over-year?
BioCryst Pharmaceuticals's ORLADEYO — total revenues increased by 10.5% year-over-year, from $134.24M to $148.35M.
What is the long-term trend for BioCryst Pharmaceuticals's ORLADEYO — total revenues?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's ORLADEYO — total revenues has grown at a 48.9% compound annual growth rate (CAGR), from $122.56M to $601.84M.
What does ORLADEYO — total revenues mean?
This metric measures the total gross or net sales generated by the specific product or business segment during a reporting period. It serves as the primary indicator of market adoption and commercial success for the asset.